A versatile system for rapid multiplex genome-edited CAR T cell generation

Oncotarget

Volumn 8, Issue 10, 2017, Pages 17002-17011

  Ren, Jiangtao ^a   Zhang, Xuhua ^a   Liu, Xiaojun ^a   Fang, Chongyun ^a   Jiang, Shuguang ^a   June, Carl H ^a   Zhao, Yangbing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CD95; Chimeric antigen receptors; CRISPR CAS9; PD 1; T lymphocytes

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA ANTIGEN CLASS 1; LENTIVIRUS VECTOR; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; CTLA4 PROTEIN, HUMAN; HYBRID PROTEIN; IL2RG PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR GAMMA; LYMPHOCYTE ANTIGEN RECEPTOR; PDCD1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CRISPR CAS SYSTEM; CRISPR CAS9 SYSTEM; CTLA4 GENE; GENE DISRUPTION; GENE EDITING; GENE LOCUS; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; MOUSE; MULTIPLEX GENOME EDITING; NONHUMAN; NORMAL HUMAN; PD1 GENE; PROMOTER REGION; T LYMPHOCYTE; ANIMAL; CELL CULTURE; DEFICIENCY; EXPERIMENTAL NEOPLASM; GENE; GENETICS; K-562 CELL LINE; KNOCKOUT MOUSE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SCID MOUSE; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELLS, CULTURED; CRISPR-CAS SYSTEMS; CTLA-4 ANTIGEN; GENE EDITING; GENES, MHC CLASS I; HUMANS; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; K562 CELLS; MICE, INBRED NOD; MICE, KNOCKOUT; MICE, SCID; NEOPLASMS, EXPERIMENTAL; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS;

EID: 85014716286     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.15218     Document Type: Article

References (37)

1. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 368:1509-18. doi: 10.1056/NEJMoa1215134.
2. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 3:95ra73. doi: 3/95/95ra73 [pii]10.1126/scitranslmed.3002842.
3. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 365:725-33. doi: 10.1056/NEJMoa1103849.
4. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 371:1507-17. doi: 10.1056/NEJMoa1407222.
5. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. doi: S0140-6736(14)61403-3 [pii]10.1016/S0140-6736(14)61403-3.
6. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 5:177ra38. doi: 5/177/177ra38 [pii] 10.1126/scitranslmed.3005930.
7. Ishizaki Y, Yukaya N, Kusuhara K, Kira R, Torisu H, Ihara K, Sakai Y, Sanefuji M, Pipo-Deveza JR, Silao CL, Sanchez BC, Lukban MB, Salonga AM, et al. PD1 as a common candidate susceptibility gene of subacute sclerosing panencephalitis. Hum Genet. 127:411-9. doi: 10.1007/s00439-009-0781-z.
8. Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, Hennart B, Allorge D, van Geel N, Van Gele M, Brochez L. Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. Oncoimmunology. 4:e982382. doi: 10.4161/2162402X.2014.982382 982382 [pii].
9. Ewing MM, Karper JC, Abdul S, de Jong RC, Peters HA, de Vries MR, Redeker A, Kuiper J, Toes RE, Arens R, Jukema JW, Quax PH. T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development. Int J Cardiol. 168:1965-74. doi: S0167-5273(12)01729-9 [pii]10.1016/j.ijcard.2012.12.085.
10. Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ, Anderson AC. TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. 2:e23849. doi: 10.4161/onci.238492012ONCOIMM0410R [pii].
11. Ngiow SF, von Scheidt B, Akiba H, Yagita H, Teng MW, Smyth MJ. Anti-TIM3 antibody promotes T cell IFNgamma-mediated antitumor immunity and suppresses established tumors. Cancer Res. 71:3540-51. doi: 0008-5472.CAN-11-0096 [pii]10.1158/0008-5472.CAN-11-0096.
12. Ngiow SF, Teng MW, Smyth MJ. Prospects for TIM3-Targeted Antitumor Immunotherapy. Cancer Res. 71:6567-71 doi: 0008-5472.CAN-11-1487 [pii]10.1158/0008-5472. CAN-11-1487.
13. Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget. 6:27359-77. doi: 10.18632/oncotarget.4751.
14. Provasi E, Genovese P, Lombardo A, Magnani Z, Liu PQ, Reik A, Chu V, Paschon DE, Zhang L, Kuball J, Camisa B, Bondanza A, Casorati G, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med. 2012; 18:807-15. doi: 10.1038/nm.2700.
15. Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, Huls H, Miller JC, Kebriaei P, Rabinovich B, Lee DA, Champlin RE, Bonini C, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood. 2012; 119:5697-705 doi: 10.1182/blood-2012-01-405365.
16. Chen X, Zachar V, Zdravkovic M, Guo M, Ebbesen P, Liu X. Role of the Fas/Fas ligand pathway in apoptotic cell death induced by the human T cell lymphotropic virus type I Tax transactivator. J Gen Virol. 1997; 78:3277-85. doi: 10.1099/0022-1317-78-12-3277.
17. Russell JH, Rush B, Weaver C, Wang R. Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci U S A. 1993; 90:4409-13.
18. Waring P, Mullbacher A. Cell death induced by the Fas/Fas ligand pathway and its role in pathology. Immunol Cell Biol. 1999; 77:312-7. doi: 10.1046/j.1440-1711.1999.00837.x.
19. Gorak-Stolinska P, Truman JP, Kemeny DM, Noble A. Activation-induced cell death of human T-cell subsets is mediated by Fas and granzyme B but is independent of TNF-alpha. J Leukoc Biol. 2001; 70:756-66. doi:
20. Maher S, Toomey D, Condron C, Bouchier-Hayes D. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol. 2002; 80:131-7. doi: 1068 [pii] 10.1046/j.1440-1711.2002.01068.x.
21. Pignatti P, Massa M, Travaglino P, Meazza C, Martini A, De Benedetti F. Activation-induced cell death and Fas-induced apoptosis in patients with systemic or pauciarticular juvenile idiopathic arthritis. Clin Exp Rheumatol. 2001; 19:339-44. doi:
22. Kunkele A, Johnson AJ, Rolczynski LS, Chang CA, Hoglund V, Kelly-Spratt KS, Jensen MC. Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasLDependent AICD. Cancer Immunol Res. 2015; 3:368-79. doi: 10.1158/2326-6066.CIR-14-0200.
23. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science. 339:819-23. doi: science.1231143 [pii] 10.1126/science.1231143.
24. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science. 339:823-6. doi: science.1232033 [pii] 10.1126/science.1232033.
25. Haurwitz RE, Jinek M, Wiedenheft B, Zhou K, Doudna JA. Sequence-and structure-specific RNA processing by a CRISPR endonuclease. Science. 329:1355-8. doi: 329/5997/1355 [pii] 10.1126/science.1192272.
26. Ren J, Liu X, Fang C, Jiang S, June CH, Zhao Y. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin Cancer Res. 2016. doi: 10.1158/1078-0432.CCR-16-1300.
27. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science. 2016; 351:84-8. doi: 10.1126/science.aad5227.
28. Brinkman EK, Chen T, Amendola M, van Steensel B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 2014; 42:e168. doi: 10.1093/nar/gku936.
29. Vidigal JA, Ventura A. Rapid and efficient one-step generation of paired gRNA CRISPR-Cas9 libraries. Nat Commun. 6:8083. doi: ncomms9083 [pii] 10.1038/ncomms9083.
30. Mandal PK, Ferreira LM, Collins R, Meissner TB, Boutwell CL, Friesen M, Vrbanac V, Garrison BS, Stortchevoi A, Bryder D, Musunuru K, Brand H, Tager AM, et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell. 2014; 15:643-52. doi: 10.1016/j.stem.2014.10.004.
31. Li C, Guan X, Du T, Jin W, Wu B, Liu Y, Wang P, Hu B, Griffin GE, Shattock RJ, Hu Q. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9. J Gen Virol. 96:2381-93. doi: 10.1099/vir.0.000139 vir.0.000139 [pii].
32. Wang W, Ye C, Liu J, Zhang D, Kimata JT, Zhou P. CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS One. 9:e115987. doi: 10.1371/journal. pone.0115987PONE-D-14-37006 [pii].
33. Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE, Haliburton GE, Ye CJ, Bluestone JA, Doudna JA, Marson A. Generation of knockin primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci U S A. 2015; 112:10437-42. doi: 10.1073/pnas.1512503112.
34. Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, Steinfeld I, Lunstad BD, Kaiser RJ, Wilkens AB, Bacchetta R, Tsalenko A, Dellinger D, et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol. 2015; 33:985-9. doi: 10.1038/nbt.3290.
35. Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, Potrel P, Bas C, Lemaire L, Galetto R, Lebuhotel C, Eyquem J, Cheung GW, et al. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. Cancer Res. 75:3853-64. doi: 0008-5472.CAN-14-3321 [pii]10.1158/0008-5472.CAN-14-3321.
36. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science. 351:84-8. doi: science. aad5227 [pii]10.1126/science.aad5227.
37. Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung JK. High-fidelity CRISPRCas9 nucleases with no detectable genome-wide off-target effects. Nature. 529:490-5. doi: nature16526 [pii]10.1038/nature16526.